Aurobindo Pharma


India's Aurobindo responds to White House urging, plans second U.S. plant

In a meeting with a host of Big Pharma execs last week, President Trump urged them to build plants and manufacture drugs in the U.S. Now a new U.S. plant has been announced but instead of coming from the invitees, it is being built by an Indian drugmaker which cited the administration’s attitude as a motivating factor.

FiercePharmaAsia: Takeda, Valeant and more

In this week's FiercePharmaAsia wrap-up, Takeda has offered $5.2 billion to buy Ariad and made a $125 deal with Maverick on T-cell therapy R&D, Valeant sold Dendreon to a Chinese company for $820 million, and more.